Program
gemigliptin
Also written as “Gemigliptin”, “Gemigliptin 50mg” and “gemigliptin/metformin HCl extended release”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LG Chem | 290 open or running | phase 4since May 24, 2013 | Oct 21, 2009 | none ahead |
| Stendhal Americas | 10 open or running | phase 1since Sep 13, 2017 | Sep 13, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Oct 21, 2009.
- Feb 5, 2014Phase 1 study in HealthyLG Chem · NCT02056600 · 24 enrolled · Korea, Republic of
- Mar 4, 20142 phase 3 studies in Diabetes Mellitus, Type 2LG Chem · NCT02126358, NCT02089126
- Dec 22, 20152 phase 1 studies in HealthyLG Chem · NCT02670070, NCT02670018
- Jun 23, 2016Phase 3 study in Diabetes Mellitus, Type 2LG Chem · NCT02831361 · 290 enrolled
- Jun 26, 2017Phase 4 study in Diabetes Mellitus, Type 2LG Chem · NCT03202563 · 71 enrolled · Korea, Republic of
- Sep 13, 2017Stendhal Americas's first study: phase 1 study in Diabetes Mellitus, Type 2New to Stendhal AmericasStendhal Americas · NCT03310749 · 34 enrolled · Mexico
- Nov 9, 2017Phase 1 study in Healthy Male VolunteersLG Chem · NCT03355014 · 70 enrolled · Korea, Republic of
- May 24, 2018Phase 1 study in Diabetes Mellitus, Type 2LG Chem · NCT03565458 · 48 enrolled · Korea, Republic of
- Feb 13, 2019Phase 3 study in Diabetes Mellitus, Type 2LG Chem · NCT03842267 · 315 enrolled · Korea, Republic of
- Mar 4, 2019Phase 1 study in Diabetes Mellitus, Type 2LG Chem · NCT03864432 · 48 enrolled · China
- Aug 21, 2019Phase 1 study in Type2 DiabetesLG Chem · NCT04070794 · 24 enrolled
- Feb 2, 2020Phase 3 study in Diabetes Mellitus, Type 2LG Chem · NCT04255238 · 468 enrolled
- Jul 29, 2020Phase 1 study in T2DMLG Chem · NCT04544319 · 44 enrolled
- Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
TargetBeta
“An orally bioavailable inhibitor of the serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic and potential renoprotective activities”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07399470Healthy Volunteers · South Korea | 1 | Completed | LG Chem | Feb 6, 2026 | 58 |
| NCT04544319T2DM | 1 | UNKNOWN | LG Chem | Mar 2021 | 44 |
| NCT04255238Diabetes Mellitus, Type 2 | 3 | UNKNOWN | LG Chem | May 30, 2022 | 468 |
| NCT04070794Type2 Diabetes | 1 | UNKNOWN | LG Chem | Nov 30, 2019 | 24 |
| NCT03864432Diabetes Mellitus, Type 2 · China | 1 | Completed | LG Chem | Oct 3, 2019 | 48 |
| NCT03842267Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | LG Chem | May 20, 2021 | 315 |
| NCT03565458Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | LG Chem | Aug 20, 2018 | 48 |
| NCT03355014Healthy Male Volunteers · Korea, Republic of | 1 | Completed | LG Chem | Jan 12, 2018 | 70 |
| NCT03310749Diabetes Mellitus, Type 2 · Mexico | 1 | Completed | Stendhal Americas | May 3, 2016 | 34 |
| NCT03202563Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | LG Chem | Jul 13, 2018 | 71 |
| NCT02831361Diabetes Mellitus, Type 2 | 3 | Completed | LG Chem | Feb 8, 2018 | 290 |
| NCT02670070Healthy · Korea, Republic of | 1 | UNKNOWN | LG Chem | Apr 2016 | 37 |
| NCT02670018Healthy · Korea, Republic of | 1 | UNKNOWN | LG Chem | Dec 2015 | 25 |
| NCT02089126Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | UNKNOWN | LG Chem | Sep 2016 | 230 |
| NCT02126358Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | LG Chem | Mar 2016 | 290 |
| NCT02056600Healthy · Korea, Republic of | 1 | Completed | LG Chem | Apr 2014 | 24 |
| NCT01990469Diabetes Mellitus, Type 2 | 3 | Completed | LG Chem | Apr 2015 | 219 |
| NCT02004587Hepatic Impairment · Germany | 1 | Completed | LG Chem | May 2014 | 28 |
| NCT01968044Renal Insufficiency · Korea, Republic of | 3 | Completed | LG Chem | Oct 2015 | 132 |
| NCT01890629Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | LG Chem | Aug 2014 | 69 |
| NCT01825850Healthy · Korea, Republic of | 1 | Completed | LG Chem | Sep 2013 | 30 |
| NCT01787396Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | LG Chem | Mar 2015 | 433 |
| NCT01768455Healthy · Korea, Republic of | 1 | Completed | LG Chem | Apr 2013 | 27 |
| NCT01662674Healthy · Korea, Republic of | 1 | Completed | LG Chem | Nov 2012 | 27 |
| NCT01603238Healthy · Korea, Republic of | 1 | Completed | LG Chem | May 2011 | 6 |
| NCT01602003Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | LG Chem | Jun 2011 | 425 |
| NCT01601990Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | LG Chem | Mar 2011 | 189 |
| NCT01595880Healthy · Korea, Republic of | 1 | Completed | LG Chem | Jan 2015 | 29 |
| NCT01426399Healthy · Korea, Republic of | 1 | Completed | LG Chem | Nov 2011 | 30 |
| NCT01001013Healthy · Korea, Republic of | 1 | Completed | LG Chem | Jun 2009 | 24 |
How it is read
Names in the registry
- “Gemigliptin”, 7 entries
- “Gemigliptin 50mg”, 5 entries
- “gemigliptin/metformin HCl extended release”, 3 entries
- “gemigliptin and metformin HCl extended release”, 3 entries
- “LC15-0444 50mg qd”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 15 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.